<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470858</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_Triple Therapy_1</org_study_id>
    <nct_id>NCT02470858</nct_id>
  </id_info>
  <brief_title>Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects</brief_title>
  <official_title>Effect of Triple Direct Acting Antiviral Agents (DAAs) for Non-cirrhotic Subjects With Chronic HCV G1b Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity and Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity and Health Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test the hypothesis that the addition of a protease inhibitor to
      dual NS5a-NS5B nucleoside prodrug analog will enhance antiviral efficacy and hence shorten
      the treatment duration to 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment.</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA levels and change during and after treatment.</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic breakthrough and relapse</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) during treatment, but did not achieve a sustained virologic response (SVR). Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>LDV/SOF+ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DCV+SMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DCV+ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF+ASV</intervention_name>
    <description>Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.</description>
    <arm_group_label>LDV/SOF+ASV</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>GS-5885</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>BMS-650032</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+DCV+SMV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>SOF+DCV+SMV</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
    <other_name>BMS-790052</other_name>
    <other_name>Daklinza®</other_name>
    <other_name>TMC435</other_name>
    <other_name>OLYSIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+DCV+ASV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.</description>
    <arm_group_label>SOF+DCV+ASV</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
    <other_name>BMS-790052</other_name>
    <other_name>Daklinza®</other_name>
    <other_name>BMS-650032</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or greater than 18 years, with chronic genotype 1b HCV infection;

          -  HCV RNA level &gt; 10,000 and &lt; 10,000,000 IU/ml at Screening;

          -  Rapid response to triple DAAs therapy with less than 500 IU/ml plasma HCV RNA level at
             Day 2;

          -  No evidence of cirrhosis. Cirrhosis defined as any 1 of the following, within 6 months
             of study entry:

               1. Liver biopsy showing cirrhosis;

               2. Fibroscan showing cirrhosis or results&gt;12.5 kPa ;

               3. FibroTest® score &gt;0.75 and an aspartate aminotransferase (AST): platelet ratio
                  index (APRI) &gt;2 during screening.

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner;

          -  HIV or chronic hepatitis B virus (HBV) infection;

          -  Hematologic or biochemical parameters at Screening outside the protocol-specified
             requirements;

          -  Active or recent history (≤ 1 year) of drug or alcohol abuse;

          -  Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers);

          -  History or current evidence of any condition, therapy, laboratory abnormality or other
             circumstance that might confound the results of the study, or interfere with the
             subject's participation for the full duration of the study, such that it is not in the
             best interest of the subject to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity and Health GI and Liver Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00852</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

